ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

VX-581

A development code.

Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.

Furthest: phase 1, since Dec 4, 20252 company-led studies, 2 open or runningNext primary completion: Jul 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals22 open or runningphase 1since Dec 4, 2025Dec 4, 2025Jul 12, 2027phase 1 · NCT07283770

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2025First study: phase 1 study in Cystic FibrosisFirst studyNCT07283770 · 152 planned · United States
  2. Sep 4, 2026Phase 1 study in Cystic FibrosisNCT07813039 · 16 enrolled · United States
  3. Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770

Ahead

  1. Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07283770

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07813039Cystic Fibrosis · United States1Active, not recruitingOct 27, 202616
NCT07283770Cystic Fibrosis · United States1RecruitingJul 12, 2027152

How it is read

Names in the registry

  • “VX-581”, 3 entries

Codes read as this program: VX581.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.